🍽️ amoxapine,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Depression: Amoxapine is FDA-approved for the treatment of depression, particularly major depressive disorder. It works by increasing the levels of neurotransmitters such as serotonin and norepinephrine in the brain, which helps improve mood and alleviate depressive symptoms.

  2. Psychotic Depression: Amoxapine may be particularly effective in treating psychotic depression, a subtype of depression characterized by the presence of psychotic symptoms such as hallucinations or delusions alongside depressive features.

  3. Off-Label Uses: In addition to depression, amoxapine may be used off-label to treat other psychiatric conditions, such as anxiety disorders, bipolar disorder, and certain types of neuropathic pain. However, its use for these indications is less common compared to other medications with similar antidepressant effects.

  4. Mechanism of Action: Like other tricyclic antidepressants, amoxapine primarily works by inhibiting the reuptake of serotonin and norepinephrine, thereby prolonging their activity at the synaptic clefts between neurons in the brain. It also antagonizes certain neurotransmitter receptors, including histamine H1 receptors and alpha-adrenergic receptors.

  5. Side Effects: Common side effects of amoxapine may include drowsiness, dizziness, blurred vision, dry mouth, constipation, urinary retention, weight gain, and sexual dysfunction. These side effects are typical of tricyclic antidepressants and may diminish over time as the body adjusts to the medication.

  6. Anticholinergic Effects: Amoxapine, like other tricyclic antidepressants, has significant anticholinergic effects, which can contribute to side effects such as dry mouth, blurred vision, constipation, and urinary retention. Elderly patients may be more susceptible to these effects and may require lower doses or closer monitoring.

  7. Cardiac Effects: Tricyclic antidepressants, including amoxapine, can prolong the QT interval on electrocardiograms (ECGs), which may increase the risk of arrhythmias, including torsades de pointes. Caution is advised when prescribing amoxapine to patients with preexisting cardiac conditions or those taking other medications that can prolong the QT interval.

  8. Withdrawal Symptoms: Abrupt discontinuation of amoxapine after long-term use may lead to withdrawal symptoms such as nausea, headache, irritability, and flu-like symptoms. To minimize the risk of withdrawal, the dose of amoxapine should be gradually tapered under medical supervision when discontinuing treatment.

  9. Overdose: Overdose of amoxapine can be serious and may result in symptoms such as seizures, cardiac arrhythmias, coma, and death. Prompt medical attention is essential in cases of suspected overdose, and supportive care, including cardiac monitoring and administration of activated charcoal or gastric lavage, may be necessary.

  10. Drug Interactions: Amoxapine may interact with other medications, including monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), anticholinergic drugs, antihypertensives, and CNS depressants. Healthcare providers should carefully evaluate potential drug interactions before prescribing amoxapine and adjust doses as needed to minimize risks.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of amoxapine,(prescription) On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces
species Bifidobacterium longum Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by amoxapine,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Phocaeicola genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Agathobacter genus Decreases 👪 Source Study
Odoribacter genus Decreases 👪 Source Study
Lachnospira genus Decreases 👪 Source Study
Akkermansia genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Segatella genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Blautia genus Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Veillonella genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Clostridioides genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Agathobacter rectalis species Decreases 📓 Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Odoribacter splanchnicus species Decreases 📓 Source Study
Lachnospira eligens species Decreases 📓 Source Study
Akkermansia muciniphila species Decreases 📓 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Bacteroides ovatus species Decreases 📓 Source Study
Bifidobacterium longum species Decreases 📓 Source Study
Blautia obeum species Decreases 📓 Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Veillonella parvula species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Dorea formicigenerans species Decreases 📓 Source Study
Clostridioides difficile species Decreases 📓 Source Study Colitis
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of amoxapine,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0 0
Acne 0.2 -0.2
ADHD 3.2 0.4 7
Age-Related Macular Degeneration and Glaucoma 0.1 0.5 -4
Allergic Rhinitis (Hay Fever) 0.7 0.5 0.4
Allergies 1.5 1.3 0.15
Allergy to milk products 0.3 0.7 -1.33
Alopecia (Hair Loss) 1.2 1.2
Alzheimer's disease 1.3 2.9 -1.23
Amyotrophic lateral sclerosis (ALS) Motor Neuron 3.1 0.8 2.88
Ankylosing spondylitis 2 0.7 1.86
Anorexia Nervosa 0.5 1.4 -1.8
Antiphospholipid syndrome (APS) 0 0
Asthma 0.9 1.5 -0.67
Atherosclerosis 0.2 1.3 -5.5
Atrial fibrillation 2.2 1.4 0.57
Autism 5.2 6.9 -0.33
Barrett esophagus cancer 0.1 0.1
Bipolar Disorder 0.8 0.5 0.6
Brain Trauma 0.2 0.3 -0.5
Carcinoma 2 1.6 0.25
Celiac Disease 1.8 2.9 -0.61
Cerebral Palsy 0.7 0.4 0.75
Chronic Fatigue Syndrome 3 4.9 -0.63
Chronic Kidney Disease 1.2 1.4 -0.17
Chronic Lyme 0.3 -0.3
Chronic Obstructive Pulmonary Disease (COPD) 0.1 0.5 -4
Chronic Urticaria (Hives) 0.1 1.5 -14
Coagulation / Micro clot triggering bacteria 0.5 0.2 1.5
Colorectal Cancer 1.6 0.6 1.67
Constipation 1.7 0.2 7.5
Coronary artery disease 0.5 0.3 0.67
COVID-19 6.9 9.1 -0.32
Crohn's Disease 3.6 4.5 -0.25
cystic fibrosis 0.4 -0.4
Depression 6.2 5.2 0.19
Dermatomyositis 0.2 -0.2
Eczema 0.1 0.4 -3
Endometriosis 1.1 1 0.1
Eosinophilic Esophagitis 0.1 -0.1
Epilepsy 1.2 3.3 -1.75
Fibromyalgia 2 1.8 0.11
Functional constipation / chronic idiopathic constipation 3.3 1.3 1.54
gallstone disease (gsd) 0.8 0.2 3
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 1.3 0.3 3.33
Generalized anxiety disorder 0.2 0.8 -3
Graves' disease 0.9 0.2 3.5
Halitosis 0.4 0.4
Hashimoto's thyroiditis 1.2 0.4 2
Hidradenitis Suppurativa 0 0.1 0
Histamine Issues,Mast Cell Issue, DAO Insufficiency 2 0.7 1.86
hypercholesterolemia (High Cholesterol) 0.5 0.8 -0.6
hyperglycemia 2.3 -2.3
Hyperlipidemia (High Blood Fats) 0.6 0.6
hypersomnia 0.2 -0.2
hypertension (High Blood Pressure 1.3 1.9 -0.46
Hypothyroidism 0.7 -0.7
Hypoxia 1.2 1.2
IgA nephropathy (IgAN) 2.9 -2.9
Inflammatory Bowel Disease 1.3 5.7 -3.38
Insomnia 0.4 0.7 -0.75
Intelligence 0.9 0.5 0.8
Intracranial aneurysms 0.9 0.9
Irritable Bowel Syndrome 1.4 4.6 -2.29
Liver Cirrhosis 2.1 1 1.1
Long COVID 4.6 4.1 0.12
Low bone mineral density 0.5 -0.5
Lung Cancer 1.1 -1.1
ME/CFS with IBS 0.9 -0.9
ME/CFS without IBS 1.2 1.6 -0.33
Menopause 0.7 0.7
Metabolic Syndrome 2.6 5.4 -1.08
Mood Disorders 7.3 5.6 0.3
multiple chemical sensitivity [MCS] 0.5 0.2 1.5
Multiple Sclerosis 3.5 4.3 -0.23
Multiple system atrophy (MSA) 1.2 0.3 3
Neuropathy (all types) 0.6 0.6
neuropsychiatric disorders (PANDAS, PANS) 0.5 0.5
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.7 4 -4.71
NonCeliac Gluten Sensitivity 0.2 -0.2
Obesity 2.7 2.8 -0.04
obsessive-compulsive disorder 4.3 3 0.43
Osteoarthritis 0.5 0.5
Osteoporosis 0.7 1.3 -0.86
pancreatic cancer 0.5 0.5
Parkinson's Disease 2.3 1.4 0.64
Polycystic ovary syndrome 1.9 1 0.9
Postural orthostatic tachycardia syndrome 0.2 -0.2
Premenstrual dysphoric disorder 0.3 0.5 -0.67
primary biliary cholangitis 0.1 0.9 -8
Psoriasis 1.2 3 -1.5
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 2.9 1.3 1.23
Rosacea 0.3 0.3
Schizophrenia 4.5 0.3 14
scoliosis 0.9 -0.9
Sjögren syndrome 2 2.5 -0.25
Sleep Apnea 0.3 0.8 -1.67
Small Intestinal Bacterial Overgrowth (SIBO) 0.3 -0.3
Stress / posttraumatic stress disorder 1.4 2 -0.43
Systemic Lupus Erythematosus 2.1 1.3 0.62
Tic Disorder 1.5 0.7 1.14
Tourette syndrome 0.4 0.3 0.33
Type 1 Diabetes 2.2 1.5 0.47
Type 2 Diabetes 3.6 4.6 -0.28
Ulcerative colitis 0.7 5.4 -6.71
Unhealthy Ageing 2.2 2 0.1

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.